It is made available under a CC-BY-NC 4.0 International license .

| 1 | Title Page |
|----|---|
| 2 | FARFOOD: A database of potential interactions between food compounds and drugs. |
| 3 | |
| 4 | Ana María Nevado-Bulnes ¹ , Dixan Agustin Benitez ² , Guadalupe Cumplido-Laso ² , Jose |
| 5 | María Carvajal-González ² , Sonia Mulero-Navarro ^{2,*} , Angel-Carlos Román ^{2,*} |
| 6 | |
| 7 | ¹ Servicio Extremeño de Salud (SES), C/Charcón s/n, 10350 – Almaraz (Spain) |
| 8 | ² Departamento de Bioquímica y Biología Molecular y Genética, Universidad de |
| 9 | Extremadura. Avda de Elvas s/n, 06071 – Badajoz (Spain) |
| 10 | |
| 11 | *Correspondence to <u>acroman@unex.es</u> , smmulero@unex.es |
| 12 | |
| 13 | This paper was supported by the Spanish Ministry of Science through the projects |
| 14 | TED2021-130036B-I00 and PID2020-117467RB-I00 (to SMN and ACR), and |
| 15 | PID2021-126905NB-I00 and TED2021-130560B-I00 (to JMCG). The authors declared |
| 16 | no competing interests for this work. |
| 17 | |
| 18 | Keywords: Food-Drug Interactions, in silico modeling, lisinopril, bupropion, allopurinol |
| 19 | |
| 20 | |
| 21 | |
| 22 | |
| 23 | |
| 24 | |

It is made available under a CC-BY-NC 4.0 International license .

25 Summary

26

27 Nutrition is a fundamental aspect in human life development, both from a socio-28 economic and medical perspective. In recent years, new personalized approaches have 29 been added to the biochemical study of nutrients. These approaches consider both the 30 effect of foods on the body and the role of genes in metabolizing or digesting different 31 nutrients. Although drug-food interactions have been known for decades, there is a lack 32 of studies that address these processes in a comprehensive way, using structural and 33 computational biochemistry techniques. In this paper we develop a method to predict 34 potential interactions between foods and drugs based on the structural similarity 35 between food compounds and medications. Our results have produced a database and an app to consult potential interactions between drugs and foods that we have called 36 37 FARFOOD. Additionally, we validated two of these potential interactions with widely 38 used drugs (lisinopril and bupropion) through structural docking between the ligand 39 protein and the food compounds that are structurally similar to the drug. Moreover, 40 patient surveys are used in the lisinopril and bupropion cases in addition to allopurinol 41 to assess the possible effects of the potentially interacting foods on the symptoms of the 42 conditions for which the medication is prescribed. In summary, this manuscript presents 43 an interesting computational resource for predictive food-drug interaction analysis.

It is made available under a CC-BY-NC 4.0 International license .

45 Introduction

46

47 Food-drug interactions are a crucial yet often underappreciated aspect of patient 48 care and therapeutic efficacy. The ingestion of certain foods can significantly alter the 49 pharmacokinetics and pharmacodynamics of drugs, impacting their absorption, 50 metabolism, and overall effectiveness (Genser, 2008; Z. Hu et al., 2005; Won et al., 51 2012). These interactions may lead to reduced therapeutic effects or, conversely, to 52 toxicity, making it essential for healthcare providers and patients to understand the role 53 diet plays in the success or failure of drug regimens (Chen et al., 2012; Koziolek et al., 54 2019; Won et al., 2012). With the rise of personalized medicine, understanding food-55 drug interactions is more important than ever, as individual genetic variations can influence how drugs and food components interact within the body (Roy et al., 2022; 56 57 Wei et al., 2024). Despite the well-documented impact of food-drug interactions on 58 clinical outcomes, systematic research and data collection in this area are limited. Most 59 current guidelines focus on well-known interactions (Bailey & Dresser, 2004; Hukkinen 60 et al., 1995; Mertens-Talcott et al., 2006; Seden et al., 2012; Sica, 2006), but there are 61 many unexplored interactions that could affect patient safety and drug efficacy, 62 especially in populations consuming diverse diets.

63

This complexity of food-drug interactions is attributed to various factors, including the biochemical properties of both drugs and food compounds. For instance, foods containing high levels of specific nutrients, such as calcium or certain fibers, can inhibit the absorption of certain medications (Aznar-Lou et al., 2019; Deng et al., 2017; Neuvonen, 1976; Stielow et al., 2023), while others, like those containing grapefruit compounds, can potentiate drug effects by inhibiting cytochrome P450 enzymes

It is made available under a CC-BY-NC 4.0 International license .

70 (Mertens-Talcott et al., 2006; Seden et al., 2012). A potential manner for detecting 71 food-drug interactions is based on structural similarity between food compounds and 72 drugs, as it has been done with drug-drug interactions (Takeda et al., 2017; Vilar et al., 73 2012). Structural similarity implies that certain bioactive compounds in foods may share 74 similar chemical structures with drug molecules, potentially leading them to bind to the 75 same target sites in the body. This structural resemblance can result in competition for 76 binding sites, altering the pharmacokinetics or pharmacodynamics of drugs. 77 Understanding these structural relationships is increasingly important for creating 78 dietary guidelines tailored to individual pharmacological needs, especially as dietary 79 diversity and self-medication continue to rise globally.

80

81 Structural similarity-based predictions provide a unique perspective for 82 analyzing interactions that might not be evident through traditional pharmacokinetic 83 studies alone. Computational approaches such as molecular docking (Agu et al., 2023), 84 quantitative structure-activity relationship (QSAR) modeling (Zaki et al., 2021), and machine learning (Roy et al., 2022) can be applied to screen food compounds against 85 86 drug targets. For example, certain polyphenols in fruits and vegetables have structural 87 motifs resembling common pharmacophores in drug molecules, allowing them to 88 interact with cytochrome P450 enzymes, potentially inhibiting or inducing drug 89 metabolism (Kimura et al., 2010). Such findings remark the need for systematic 90 screening of food compounds using computational models, which could help predict 91 and ultimately prevent adverse interactions. This highlights the potential of using 92 structural similarity as a predictive tool in food-drug interaction research, where 93 identifying molecular similarities between food and drug compounds can lead to 94 proactive dietary or medicament doses recommendations.

It is made available under a CC-BY-NC 4.0 International license .

95

| 96 | The main aim of this manuscript is to develop a comprehensive computational | |
|-----|---|--|
| 97 | resource for potential interactions between drugs and food compounds based on | |
| 98 | structural similarity. Other recent approaches have used gene expression and other | |
| 99 | sources for the development of similar databases (Lacruz-Pleguezuelos et al., 2023). We | |
| 100 | considered as hypothesis that if two molecules have a very similar structure, then they | |
| 101 | might interact with the same protein targets. We validated some of these interactions | |
| 102 | using (i) in silico docking experiments that showed how both the drug and the food | |
| 103 | compound can bind to the same protein region and (ii) patient surveys in which we | |
| 104 | correlate disease parameters with the consumption of foods that contain the potentiall | |
| 105 | interacting compound. | |
| | | |

106

It is made available under a CC-BY-NC 4.0 International license .

108 Materials and Methods

109

110 Input food compound and drug data

111 For food-related data, we utilized version 1.0 of FooDB (www.foodb.ca), a 112 comprehensive, publicly funded database supported by the Canadian Institutes of 113 Health. FooDB provides extensive information on the biology and chemistry of food 114 components, including macronutrients, micronutrients, and attributes like color, aroma, 115 flavor, and texture. Each food component entry includes over 100 fields covering 116 nomenclature, structural and physicochemical properties, food sources, concentrations, 117 physiological effects, and potential health impacts (Sanchez-Ruiz & Colmenarejo, 118 2021). For our structural similarity analysis, we used only the structural data (compound 119 ID and SMILES format), while food source and concentration data were applied in later 120 analyses and for the app development. For drug information, we employed version 15 of 121 CHEMBL (www.ebi.ac.uk/chembl), a manually curated database of bioactive 122 molecules maintained by the European Bioinformatics Institute (Gaulton et al., 2011). 123 CHEMBL includes structural data as well as physicochemical and pharmacological 124 properties for each molecule, such as molecular weight, Lipinski parameters, ADME 125 properties, and molecular targets. We filtered CHEMBL entries to include only 126 molecules approved or in late-stage studies, narrowing the dataset from over two 127 million entries to approximately 10,000 compounds. For subsequent analyses and the 128 app, we included each drug's generic name and physicochemical and pharmacological 129 characteristics.

130

131 Structural comparison between food compounds and drugs

It is made available under a CC-BY-NC 4.0 International license .

132 To identify potential interactions between food compounds and drugs, we 133 conducted a structural similarity analysis between each food compound and drug. This 134 one-to-one comparison across over 70,000 food compounds and more than 10,000 135 drugs results in over 700 million possible pairwise comparisons. Due to the scale, these 136 comparisons were automated using a computational algorithm to process, compare, and 137 analyze each compound-drug pair. To facilitate this process, we developed a PERL 138 script that utilizes an external software tool, Open Babel (www.openbabel.org) 139 (O'Boyle et al., 2011), to generate a list of food compound/drug pairs with structural 140 similarity above a defined threshold. For similarity measurement, we employed the 141 Tanimoto index (Tanimoto, 1958), a widely-used metric in cheminformatics based on 142 molecular fingerprints—a binary encoding of the molecular structure (Willett et al., 143 1986). Each fingerprint represents the presence or absence of specific substructures 144 within a molecule using binary bits. By setting a threshold, we identified molecule pairs 145 that met or exceeded this similarity score, with higher threshold values indicating 146 greater structural similarity.

147

148 **Design of FARFOOD database and app**

149 The molecule pairs with Tanimoto index > 0.7 were selected, and the 150 information obtained from the FooDB and CHEMBL databases was stored as data 151 tables in MATLAB. To generalize and simplify access to the FARFOOD database, we 152 developed a cross-platform app using MATLAB's Application Designer. The app is 153 compatible with Windows, Linux, and macOS, though it requires users to install the 154 free MATLAB Runtime environment. The app is distributed as an executable file that 155 can be downloaded from http://www.github.com/acroman. The FARFOOD app provides access to the database information, allowing users to explore drug-food 156

It is made available under a CC-BY-NC 4.0 International license .

157 compound interactions, as well as detailed data from CHEMBL and FooDB. The app's 158 interface prioritizes simplicity, featuring a search bar at the top, a dropdown menu to 159 select either "CHEMBL ID" or "CHEMBL name," and a search button for easy 160 querying. The app is centered around drugs, enabling users to quickly identify potential 161 food interactions for any drug of interest. To enrich the interaction data, the app links 162 interaction results with additional details on compounds, including the foods containing 163 each compound and their concentrations. This information is shown in a lower app 164 window when the user clicks on a compound, enabling a comprehensive view of food 165 sources and concentrations for each compound involved in a drug interaction.

166

167 Molecular docking

168 To validate potential interactions between structurally similar food compounds 169 and drugs, we employed a molecular docking approach (Shoichet, 2004). Docking 170 analyses require the structure of the target protein and the potential ligand as input, 171 producing one or more bound conformations of the ligand-protein complex as output. 172 We selected the target protein for each drug as identified in the FARFOOD database, 173 which draws on CHEMBL for target information. PDB files for each protein were 174 downloaded from the Protein Data Bank (Berman et al., 2000). For ligands, we used 175 both the drug (as a positive control) and the structurally similar food compound. Drug 176 structures were obtained from CHEMBL, while food compound structures were 177 retrieved from FooDB and converted from SMILES to PDB format using Open Babel. 178 Docking was performed using DockThor (https://www.dockthor.lncc.br/v2/) (Guedes et 179 al., 2024), a public server supporting interactive docking. Default conditions, including 180 blind docking, were applied to ensure comprehensive exploration of binding sites.

It is made available under a CC-BY-NC 4.0 International license .

182 **Patient surveys**

183 Patients with specific drug prescription from the regional healthcare area of 184 Almaraz were contacted by phone. They were asked for their habits of food 185 consumption (using foods that contain potentially interacting compounds as well as 186 other –control- types of food). These results were normalized using the following scale: 187 0-never; 1-sporadically, once in months; 2- at least once per week; 3-daily consumption. 188 In addition, they were asked for specific symptoms or characteristics about the diseases 189 related to the prescription. A minimum of 20 patients were asked for each drug 190 analyzed, and the demographic data (age and sex) can be consulted in Table 1. The 191 study protocol was reviewed by the Ethics Board of the University of Extremadura, and 192 approved with the reference number 167/2023.

193

194

It is made available under a CC-BY-NC 4.0 International license .

196 **Results**

197

198 Design of a database of potential interactions between drug and food compounds 199 using structural similarity

200 First we designed a workflow that detected potential interactions between drug 201 and food compounds based on the structural similarity of each molecule (Figure 1A). 202 Specifically, we compared the structure of each drug present in CHEMBL database 203 (N=10,650) with each food compound present in FooDB database (N=70,477). We 204 retrieved the pairwise relations that presented a Tanimoto Index equal or above 0.7, 205 resulting in 657,219 potential interactions between drugs and food compounds. We 206 compiled specific information from both databases in a MATLAB application that can 207 be freely used (Figure 1B). With this application, a user can search for a specific drug, 208 and the database will return the specific compounds with structural similarity (Tanimoto 209 Index equal or above 0.7, the food in which this compound has been detected and its 210 relative concentration, if known. As expected, the number of drugs that present potential 211 interactions with food compounds decreases if we increase the Tanimoto Index 212 threshold (Figure 1C). More than 2,500 drugs in the CHEMBL database present 213 structural similarities with a Tanimoto Index threshold of 0.7, while more than 1,000 214 drugs still present structural similarities with a threshold of 0.9. The specificity of the 215 potential interactions that were predicted is supported because most of the drugs 216 presented only 1-5 interactions with compounds (Figure 1D). This data showed that a 217 relevant number of known drugs presented structural similarity to food compounds and 218 their specificity suggested that they might become candidates for a source of food-drug 219 interactions.

It is made available under a CC-BY-NC 4.0 International license .

221 Study of the pharmacological and chemical properties of candidate drugs

222 We explored further the drugs that presented structural similarity with food 223 compounds, using some of their pharmacological and chemical properties that were 224 contained in CHEMBL database. The majority (56%) of these drugs were synthetic 225 small molecules, while 35% of them were from natural origin, a property that could be 226 linked to their similarity to natural food compounds (Figure 2A). The structure of these 227 drugs mainly presented single steroisomerism (47%), with a representative percentage 228 (27%) being achiral molecules (Figure 2B). As this study focused in the detection of 229 potential interactions between drugs and food compounds, it was very relevant for us to 230 assess the percentage of these drugs that are orally administered, as they might directly 231 interact with the food compounds. We observed that 12% of the drugs that presented 232 structural similarity with food compounds were orally administered (Figure 2C). In 233 addition, one of the main classic methods to determine the potential oral bioavailability 234 of a drug is the Rule of Lipinski or Rule of 5, that characterize the pharmacokinetic 235 properties of a drug. In this case, 62% of the drugs with potential food interactions 236 fulfilled this Rule (Figure 2D). Finally, it was also interesting to assess the novelty of 237 these drugs, but a low percentage (1%) of them were the first-of-class drug on its area 238 (Figure 2E). This exploratory study confirms that several drug candidates can physically 239 share the space with food compounds, leading to a more severe interaction in the 240 digestive system.

241

242 Study case of lisinopril and its potential interaction with cyclosquamosin A.

Lisinopril is a peptidyl dipeptidase inhibitor classified under ACE inhibitors (angiotensin-converting enzyme inhibitors) (Chase & Sutton, 1989; Lancaster & Todd, 1988). It functions by competitively inhibiting the ACE enzyme, which catalyzes the

It is made available under a CC-BY-NC 4.0 International license .

246 conversion of angiotensin I to the vasoconstrictor peptide angiotensin II. Angiotensin II 247 also stimulates aldosterone secretion by the adrenal cortex. Inhibiting ACE reduces 248 angiotensin II levels, leading to decreased vasopressor activity and reduced aldosterone 249 secretion, which may increase serum potassium levels. Through this mechanism, 250 lisinopril acts as a potent vasodilator for both veins and arteries, producing prolonged 251 hypotensive effects. Lisinopril is primarily indicated for hypertension, offering 252 advantages over other antihypertensives as it does not interfere with carbohydrate, lipid, 253 or uric acid metabolism. Additionally, it is used to treat conditions such as heart failure, 254 acute myocardial infarction, and diabetic nephropathy. A common side effect is a 255 persistent dry cough, which may lead some patients to discontinue treatment (Y. Hu et 256 al., 2023). According to DrugStats, lisinopril was the fourth most prescribed drug in the 257 United States in 2020, with 88,597,017 prescriptions for 19,816,361 patients.

258

259 In terms of potential food-drug interactions, the FARFOOD database estimated 260 its structural similarity with cyclosquamosin A (Figure 3A, top). Cyclosquamosin A is a 261 compound found in tropical fruits such as cherimoya (Yang et al., 2008). Interestingly, 262 other compounds from its same family showed vasorelaxant and anti-inflammatory 263 activities (Morita et al., 2006; Yang et al., 2008). Since the molecular target of lisinopril 264 (ACE) is known, we performed docking analyses to examine whether cyclosquamosin 265 A binds to the same site. It is shown that both compounds have affinity for the same 266 binding region on ACE (Figure 3A, middle). A closer look at the binding pocket (Figure 267 3A, bottom) reveals that both compounds occupy the same pocket on ACE, with 268 cyclosquamosin A forming even more interactions. This supports the possibility of an 269 interaction between the two molecules. In order to confirm this, we studied if the 270 consumption of tropical fruits (with content of cyclosquamosin A) in lisinopril patients

It is made available under a CC-BY-NC 4.0 International license .

was associated to the presence of past myocardial infarctions (Figure 3B, top). We statistically observed that the consumption of tropical fruits was associated to the absence of myocardial infarctions, while this association was not observed in the case of other fruit consumption (Figure 3B, bottom). This result supports the idea of a potential interaction between cyclosquamosin A and lisinopril.

276

277 Study case of bupropion and its potential interaction with hydroxybupropion.

278 Bupropion is classified under the therapeutic category of other antidepressants 279 and is primarily indicated for major depressive episodes (Dhillon et al., 2008; Patel et 280 al., 2016). Its mechanism of action involves the selective inhibition of catecholamine 281 reuptake, specifically norepinephrine and dopamine, with minimal effect on serotonin 282 reuptake and no inhibition of monoamine oxidase (Stahl et al., 2004). This selective 283 inhibition leads to an increase in neurotransmitters within the synaptic cleft, which is 284 associated with improved mood and a sense of well-being. Bupropion is also approved 285 as a smoking cessation aid for patients with nicotine dependence, although the exact 286 mechanism for this effect is not fully understood. It is believed to involve 287 noradrenergic and/or dopaminergic pathways (Simon et al., 2004). According to 288 DrugStats, bupropion was the 18th most prescribed medication in the United States in 289 2020, with 28,889,368 prescriptions for 5,801,282 patients.

290

Structural similarity analysis revealed that only hydroxybupropion, a metabolite of bupropion (Connarn et al., 2016), shares a significant structural resemblance with bupropion itself (Tanimoto index = 0.875; Figure 4A, top). Following FooDB, hydroxybupropion has been detected, although not quantified, in various foods such as black gram beans (*Vigna mungo*), chicory leaves (*Cichorium intybus var. foliosum*), red

It is made available under a CC-BY-NC 4.0 International license .

296 currants (Ribes rubrum), and European chestnuts (Castanea sativa). Given that the 297 molecular target of bupropion is known (the dopamine transporter, DAT) (Nemeroff & 298 Owens, 2009), a docking analysis was conducted to assess whether hydroxybupropion 299 binds to the same region on DAT using the DockThor server. As shown in figure 4A 300 (middle), both compounds bound to the same region of DAT, supporting the hypothesis 301 that hydroxybupropion may interfere with the effect of bupropion if consumed through 302 foods containing this metabolite. A closer examination of the binding site (Figure 4A, 303 bottom) illustrates the significant overlap in the binding positions of both molecules, 304 further supporting the potential for interaction. Previous works suggested that 305 hydroxybupropion can also reduce depression (Damaj et al., 2004), so we studied if the 306 patterns in hydroxybupropion-containing food consumption can interact with 307 parameters related to bupropion prescription. In this case, we observed that the 308 consumption of chestnuts (food that contains hydroxybupropion) is statistically 309 associated to mild instead of severe depression in the bupropion patients (Figure 4B, 310 top). In the case of a control food that does not contain hydroxybupropion, as milk, we 311 did not observe the same trend (Figure 4B, bottom). As in with lisinopril, this survey 312 data points to an interaction between the drug and the food compound, or in this case 313 bupropion and chestnut consumption.

314

315 Study case of allopurinol and its potential interaction with oxypurinol.

Allopurinol is classified as a uric acid production inhibitor, working primarily by inhibiting xanthine oxidase (Gibson et al., 1982; Seth et al., 2014). This enzyme is responsible for converting hypoxanthine to xanthine and xanthine to uric acid. By blocking this pathway, allopurinol reduces uric acid levels both in plasma and urine (Gibson et al., 1982; Seth et al., 2014). Due to this mechanism, allopurinol is indicated

It is made available under a CC-BY-NC 4.0 International license .

321 for treating clinical manifestations associated with uric acid deposition, such as gouty 322 arthritis, cutaneous tophi, and kidney complications involving urate crystal deposits or 323 kidney stones. Gout, often the primary manifestation of uric acid buildup, can be 324 aggravated by lifestyle and dietary factors. Foods high in purines, such as red meat and 325 seafood, as well as fructose-rich fruits and vegetables, exacerbate the condition (Choi et 326 al., 2004). Conversely, certain foods may alleviate gout symptoms; for example, 327 cherries have been shown to be associated with lower uric acid levels and reduced gout 328 attacks (Zhang et al., 2012). Cherries contain anthocyanins, antioxidants that help 329 decrease inflammation. According to DrugStats, allopurinol was the 42nd most 330 prescribed medication in the United States in 2020, with 36,600,871 prescriptions for 331 3,606,249 patients, moving up one rank from 2019.

332

333 A structurally similar compound, oxypurinol (Tanimoto index = 0.88), was 334 identified as present at high concentrations in beer (Ka et al., 2006). Previous studies 335 have shown how oxypurinol and allopurinol share xanthine oxidase as protein target 336 (Sekine et al., 2023). Interestingly, they suggested that the mechanism of inhibition 337 could be different in both compounds. This led us to investigate whether beer 338 consumption, with its higher concentration of oxypurinol, might impact patients in the 339 patients who were prescribed allopurinol. We assessed beer consumption and gout/uric 340 acid-related symptoms to determine any correlation. Beer consumption was clearly 341 associated with gout symptoms, particularly in terms of the number of affected joints 342 and the duration of gout attacks, while the frequency of attacks was less significantly 343 correlated (Figure 5A). Patients were also surveyed regarding their consumption of 344 other foods, including red meat. Interestingly, the only significant correlation with red 345 meat consumption was the frequency of gout attacks-the variable less associated with

It is made available under a CC-BY-NC 4.0 International license .

346 beer consumption (Figure 5B). This data suggests that the consumption of beer is

347 affecting gout symptoms through a different way as the consumption of red meat,

- 348 pointing to the possible effect of the presence of oxypurinol and its interaction with
- 349 allopurinol.
- 350
- 351

It is made available under a CC-BY-NC 4.0 International license .

352 Discussion

353

354 In this paper, we developed a novel database with potential interactions between 355 drugs and food compounds. Our hypothesis is grounded in the principle that a drug's 356 effect results from its interaction with one or more specific molecular targets, typically 357 proteins, which are activated or inhibited by the drug, either through direct binding or 358 competition with other ligands. The pharmacological response observed arises from this 359 alteration in protein activity, as described in Goodman and Gilman's Manual of 360 Pharmacology and Therapeutics (Goodman and Gilman 2011), where it is noted that the 361 effects of most drugs are mediated through their interactions with macromolecular 362 components of the body. While our hypothesis is theoretically sound and supported by existing pharmacological frameworks (Shoichet, 2004), there are still potential 363 364 limitations in our analysis that could lead to false positives within the FARFOOD 365 database predictions.

366

367 One major limitation concerns the bioavailability of food compounds at the 368 target site. Many ingested food compounds undergo extensive metabolism in the 369 digestive tract and may be transformed before reaching the bloodstream or may be 370 entirely excreted, thus never reaching the intended target cells. A solution to this 371 limitation could involve verifying whether the predicted food compounds are indeed 372 present in human plasma. The Human Metabolome Project (Wishart et al., 2022) is a 373 valuable resource, containing data on over 35,000 metabolites detected in blood, and 374 could serve as an experimental filter to validate the presence of specific compounds in 375 circulation. By cross-referencing FARFOOD predictions with experimentally detected

It is made available under a CC-BY-NC 4.0 International license .

376 metabolites, we could enhance the reliability of our predictions, focusing on interactions

- 377 with compounds confirmed in the bloodstream.
- 378

379 Another consideration is whether our selected Tanimoto index threshold (≥ 0.7) 380 is restrictive enough to minimize false positives. While a higher Tanimoto index implies 381 greater structural similarity and then a higher likelihood of interaction, it is crucial to 382 balance sensitivity with specificity. To address this, the Tanimoto index is clearly 383 displayed in the app interface, providing users with transparency regarding the 384 interaction likelihood. Furthermore, the molecular docking analyses of lisinopril and 385 bupropion to evaluate the binding affinity between the drug and its receptor in 386 comparison with structurally similar food compounds showed a positive result. Docking 387 studies, which are well-validated across numerous publications (Sousa et al., 2006; 388 Trott & Olson, 2010), suggest that our computational predictions can reflect 389 experimentally observed binding behaviors. Nonetheless, experimental validation 390 remains necessary, and it could include in vitro assays where recombinant target 391 proteins are incubated with mixtures of the drug and food compound to determine 392 kinetic parameters and binding affinities. Since macromolecular targets are often 393 located on cell surfaces or within specific intracellular compartments, *in vitro* testing 394 would provide a precise measure of how food compounds influence the 395 pharmacodynamics of drugs at the cellular level.

396

Moreover, our dietary habit surveys and symptom tracking for patients taking specific medications also support the existence of interactions between drugs (lisinopril, bupropion and allopurinol) and structurally similar food compounds. The survey findings align with our computational predictions and provide real-world evidence of

It is made available under a CC-BY-NC 4.0 International license .

401 these interactions, but it remains unclear the effect (agonist or antagonist) of the food 402 compound with the drug. In two examples (lisinopril and bupropion), the consumption 403 of the structurally similar food compounds correlated with positive clinical measures of 404 the patients, while in the other example (allopurinol), the consumption of the food was 405 associated to a negative impact in the disease.

406

407 Additionally, a promising line for future work involves developing a Polygenic 408 Risk Score (PRS)-like approach (Kachuri et al., 2023; Kullo et al., 2022) tailored to 409 food-drug interactions. By focusing on the target proteins listed in FARFOOD, we 410 could identify and map the genes encoding these proteins, as genetic variations 411 impacting these targets would likely alter the efficacy of drugs and the action of 412 structurally similar food compounds. If we extend this analysis to food items containing 413 multiple bioactive compounds, we could construct a PRS-like method specifically for 414 food-related interactions. This approach would allow us to identify individuals with a 415 high risk for a particular food, indicating a potential predisposition to altered drug 416 responses when consuming that food. In summary, our study highlights the potential of 417 FARFOOD as a predictive tool for identifying food-drug interactions, though further 418 validation and refinement of these predictive methods are essential for achieving 419 clinically relevant outcomes.

420

It is made available under a CC-BY-NC 4.0 International license .

422 Study Highlights

423

424 What is the current knowledge on the topic?

425 Food-Drug Interactions is a relevant and well-studied field in Pharmacology.

426 Nevertheless, these interactions are detected in a case-by-case manner, leading to

427 multiple undetected interactions with mild consequences in pharmacokinetics.

428 What question did this study address?

429 This study uses structural similarity between compounds as a method to predict

430 potential interactions due to similar protein binding. Using a drug-wide and food-wide

431 system, we predict multiple potential interactions between drugs and food compounds.

432 What does this study add to our knowledge?

- 433 The main result of this study is a database/application that contains the similarities (and
- 434 therefore the potential interactions) between drugs and food compounds; in addition, we

435 validate three of these predictions using *in silico* docking as well as patient surveys.

436 How might this change clinical pharmacology or translational science?

437 These results can lead to a deeper analysis of specific drug/food compounds in order to

438 validate additional interactions, and then to novel nutritional recommendations for

- 439 medicated patients.
- 440

It is made available under a CC-BY-NC 4.0 International license .

442 Author Contributions

- 443
- 444 A.C.R. wrote the manuscript; A.C.R. and S.M.N. designed the research; A.M.N.B.
- 445 performed the research; A.M.N.B., G.C.L., D.A.B and J.M.C.G. analyzed the data;
- 446
- 447
- 448

It is made available under a CC-BY-NC 4.0 International license .

449 Acknowledgements

- 450
- 451 This paper was supported by the Spanish Ministry of Science through the
- 452 projects TED2021-130036B-I00 and PID2020-117467RB-I00 (to SMN and
- 453 ACR), and PID2021-126905NB-I00 and TED2021-130560B-I00 (to JMCG).
- 454

It is made available under a CC-BY-NC 4.0 International license .

455 **References**

| 457 | Agu, P. C., Afiukwa, C. A., Orji, O. U., Ezeh, E. M., Ofoke, I. H., Ogbu, C. O., |
|-----|--|
| 458 | Ugwuja, E. I., & Aja, P. M. (2023). Molecular docking as a tool for the discovery |
| 459 | of molecular targets of nutraceuticals in diseases management. Scientific Reports |
| 460 | 2023 13:1, 13(1), 1–18. https://doi.org/10.1038/s41598-023-40160-2 |
| 461 | Aznar-Lou, I., Carbonell-Duacastella, C., Rodriguez, A., Mera, I., & Rubio-Valera, M. |
| 462 | (2019). Prevalence of Medication-Dietary Supplement Combined Use and |
| 463 | Associated Factors. Nutrients, 11(10), 2466. https://doi.org/10.3390/NU11102466 |
| 464 | Bailey, D. G., & Dresser, G. K. (2004). Interactions between grapefruit juice and |
| 465 | cardiovascular drugs. Am J Cardiovasc Drugs, 4(5), 281–297. |
| 466 | https://doi.org/10.2165/00129784-200404050-00002 |
| 467 | Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., |
| 468 | Shindyalov, I. N., & Bourne, P. E. (2000). The Protein Data Bank. Nucleic Acids |
| 469 | Research, 28(1), 235–242. https://doi.org/10.1093/NAR/28.1.235 |
| 470 | Chase, S. L., & Sutton, J. D. (1989). Lisinopril: A New Angiotensin Converting |
| 471 | Enzyme Inhibitor. Pharmacotherapy: The Journal of Human Pharmacology and |
| 472 | <i>Drug Therapy</i> , 9(3), 120–128. https://doi.org/10.1002/j.1875-9114.1989.tb04117.x |
| 473 | Chen, XW., Sneed, K. B., Pan, SY., Cao, C., Kanwar, J. R., Chew, H., & Zhou, SF. |
| 474 | (2012). Herb-drug interactions and mechanistic and clinical considerations. |
| 475 | Current Drug Metabolism, 13(5), 640–651. |
| 476 | https://doi.org/10.2174/1389200211209050640 |
| 477 | Choi, H. K., Atkinson, K., Karlson, E. W., Willett, W., & Curhan, G. (2004). Purine- |
| 478 | Rich Foods, Dairy and Protein Intake, and the Risk of Gout in Men. New England |
| 479 | Journal of Medicine, 350(11), 1093-1103. https://doi.org/10.1056/nejmoa035700 |
| 480 | Connarn, J. N., Luo, R., Windak, J., Zhang, X., Babiskin, A., Kelly, M., Harrington, G., |
| 481 | Ellingrod, V. L., Kamali, M., McInnis, M., & Sun, D. (2016). Identification of |
| 482 | non-reported bupropion metabolites in human plasma. Biopharmaceutics & Drug |
| 483 | Disposition, 37(9), 550-560. https://doi.org/10.1002/BDD.2046 |
| 484 | Damaj, M. I., Carroll, F. I., Eaton, J. B., Navarro, H. A., Blough, B. E., Mirza, S., |
| 485 | Lukas, R. J., & Martin, B. R. (2004). Enantioselective effects of hydroxy |
| 486 | metabolites of bupropion on behavior and on function of monoamine transporters |
| 487 | and nicotinic receptors. <i>Molecular Pharmacology</i> , 66(3), 675–682. |
| 488 | https://doi.org/10.1124/MOL.104.001313 |
| 489 | Deng, J., Zhu, X., Chen, Z., Fan, C. H., Kwan, H. S., Wong, C. H., Shek, K. Y., Zuo, |
| 490 | Z., & Lam, T. N. (2017). A Review of Food–Drug Interactions on Oral Drug |
| 491 | Absorption. Drugs 2017 77:17, 77(17), 1833–1855. |
| 492 | https://doi.org/10.1007/S40265-017-0832-Z |
| 493 | Dhillon, S., Yang, L. P. H., & Curran, M. P. (2008). Bupropion: a review of its use in |
| 494 | the management of major depressive disorder. <i>Drugs</i> , 68(5), 653–689. |
| 495 | https://doi.org/10.2165/00003495-200868050-00011 |
| 496 | Gaulton, A., Bellis, L. J., Bento, A. P., Chambers, J., Davies, M., Hersey, A., Light, Y., |
| 497 | McGlinchey, S., Michalovich, D., Al-Lazikani, B., & Overington, J. P. (2011). |
| 498 | ChEMBL: a large-scale bioactivity database for drug discovery. <i>Nucleic Acids</i> |
| 499 | Research, 40(Database issue), D1100. https://doi.org/10.1093/NAR/GKR777 |
| 500 | Genser, D. (2008). Food and drug interaction: consequences for the nutrition/health |
| 501 | status. Annals of Nutrition & Metabolism, 52 Suppl 1(SUPPL. 1), 29–32. |
| 502 | https://doi.org/10.1159/000115345 |

| 503 | Gibson, T., Rodgers, V., Potter, C., & Simmonds, H. A. (1982). Allopurinol treatment | | |
|-----|--|--|--|
| 504 | and its effect on renal function in gout: A controlled study. Annals of the | | |
| 505 | Rheumatic Diseases, 41(1), 59–65. https://doi.org/10.1136/ARD.41.1.59 | | |
| 506 | 5 Goodman and Gilman's Manual of Pharmacology and Therapeutics, 2e / | | |
| 507 | AccessPharmacy / McGraw Hill Medical. (n.d.). Retrieved November 14, 2024, | | |
| 508 | from https://accesspharmacy.mhmedical.com/book.aspx?bookid=1810 | | |
| 509 | Guedes, I. A., Pereira da Silva, M. M., Galheigo, M., Krempser, E., de Magalhães, C. | | |
| 510 | S., Correa Barbosa, H. J., & Dardenne, L. E. (2024). DockThor-VS: A Free | | |
| 511 | Platform for Receptor-Ligand Virtual Screening. Journal of Molecular Biology, | | |
| 512 | 436(17), 168548. https://doi.org/10.1016/J.JMB.2024.168548 | | |
| 513 | Hu, Y., Liang, L., Liu, S., Kung, J. Y., & Banh, H. L. (2023). Angiotensin-converting | | |
| 514 | enzyme inhibitor induced cough compared with placebo, and other | | |
| 515 | antihypertensives: A systematic review, and network meta-analysis. <i>Journal of</i> | | |
| 516 | Clinical Hypertension (Greenwich, Conn.), 25(8), 661–688. | | |
| 517 | https://doi.org/10.1111/JCH.14695 | | |
| 518 | Hu, Z., Yang, X., Ho, P. C. L., Sui, Y. C., Heng, P. W. S., Chan, E., Duan, W., Hwee, | | |
| 519 | L. K., & Zhou, S. (2005). Herb-drug interactions: A literature review. <i>Drugs</i> . | | |
| 520 | 65(9), 1239–1282. https://doi.org/10.2165/00003495-200565090-00005 | | |
| 521 | Hukkinen, S. K., Varhe, A., Olkkola, K. T., & Neuvonen, P. J. (1995). Plasma | | |
| 522 | concentrations of triazolam are increased by concomitant ingestion of grapefruit | | |
| 523 | juice. Clin Pharmacol Ther, 58(2), 127–131, https://doi.org/10.1016/0009- | | |
| 524 | 9236(95)90188-4 | | |
| 525 | Ka, T., Moriwaki, Y., Inokuchi, T., Yamamoto, A., Takahashi, S., Tsutsumi, Z., & | | |
| 526 | Yamamoto, T. (2006). Effects of allopurinol on beer-induced increases in plasma | | |
| 527 | concentrations and urinary excretion of purine bases (uric acid, hypoxanthine, and | | |
| 528 | xanthine). Hormone and Metabolic Research = Hormon- Und | | |
| 529 | Stoffwechselforschung = Hormones et Metabolisme, 38(3), 188–192. | | |
| 530 | https://doi.org/10.1055/S-2006-925429 | | |
| 531 | Kachuri, L., Chatterjee, N., Hirbo, J., Schaid, D. J., Martin, I., Kullo, I. J., Kenny, E. E., | | |
| 532 | Pasaniuc, B., Auer, P. L., Conomos, M. P., Conti, D. V., Ding, Y., Wang, Y., | | |
| 533 | Zhang, H., Zhang, Y., Witte, J. S., & Ge, T. (2023). Principles and methods for | | |
| 534 | 4 transferring polygenic risk scores across global populations. <i>Nature Reviews</i> | | |
| 535 | 5 Genetics 2023 25:1, 25(1), 8–25. https://doi.org/10.1038/s41576-023-00637-2 | | |
| 536 | Kimura, Y., Ito, H., Ohnishi, R., & Hatano, T. (2010). Inhibitory effects of polyphenols | | |
| 537 | on human cytochrome P450 3A4 and 2C9 activity. Food and Chemical | | |
| 538 | Toxicology, 48(1), 429–435. https://doi.org/10.1016/J.FCT.2009.10.041 | | |
| 539 | Koziolek, M., Alcaro, S., Augustijns, P., Basit, A. W., Grimm, M., Hens, B., Hoad, C. | | |
| 540 | L., Jedamzik, P., Madla, C. M., Maliepaard, M., Marciani, L., Maruca, A., Parrott, | | |
| 541 | N., Pávek, P., Porter, C. J. H., Reppas, C., van Riet-Nales, D., Rubbens, J., | | |
| 542 | Statelova, M., Corsetti, M. (2019). The mechanisms of pharmacokinetic food- | | |
| 543 | drug interactions – A perspective from the UNGAP group. European Journal of | | |
| 544 | Pharmaceutical Sciences, 134, 31–59. https://doi.org/10.1016/J.EJPS.2019.04.003 | | |
| 545 | Kullo, I. J., Lewis, C. M., Inouye, M., Martin, A. R., Ripatti, S., & Chatterjee, N. | | |
| 546 | (2022). Polygenic scores in biomedical research. Nat. Rev. Genet., 23(9), 524-532. | | |
| 547 | https://doi.org/10.1038/s41576-022-00470-z | | |
| 548 | Lacruz-Pleguezuelos, B., Piette, O., Garranzo, M., Pérez-Serrano, D., Milešević, J., | | |
| 549 | Espinosa-Salinas, I., de Molina, A. R., Laguna, T., & de Santa Pau, E. C. (2023). | | |
| 550 | FooDrugs: a comprehensive food-drug interactions database with text documents | | |
| 551 | and transcriptional data. Database, 2023. | | |
| 552 | https://doi.org/10.1002/DATADASE/DAAD075 | | |

552 https://doi.org/10.1093/DATABASE/BAAD075

| 553 | Lancaster, S. G., & Todd, P. A. (1988). Lisinopril. A preliminary review of its | | | |
|-----|--|--|--|--|
| 554 | pharmacodynamic and pharmacokinetic properties, and therapeutic use in | | | |
| 555 | hypertension and congestive heart failure. Drugs, 35(6), 646–669. | | | |
| 556 | https://doi.org/10.2165/00003495-198835060-00003 | | | |
| 557 | Mertens-Talcott, S. U., Zadezensky, I., Castro, W. V. De, Derendorf, H., & Butterweck, | | | |
| 558 | V. (2006). Grapefruit-drug interactions: can interactions with drugs be avoided. J | | | |
| 559 | Clin Pharmacol, 46(12), 1390–1416. https://doi.org/10.1177/0091270006294277 | | | |
| 560 | Morita, H., Iizuka, T., Choo, C. Y., Chan, K. L., Takeya, K., & Kobayashi, J. (2006). | | | |
| 561 | Vasorelaxant activity of cyclic peptide, cyclosquamosin B, from Annona | | | |
| 562 | squamosa. Bioorganic & Medicinal Chemistry Letters, 16(17), 4609–4611. | | | |
| 563 | https://doi.org/10.1016/J.BMCL.2006.06.008 | | | |
| 564 | Nemeroff, C. B., & Owens, M. J. (2009). The role of serotonin in the pathophysiology | | | |
| 565 | of depression: As important as ever. <i>Clinical Chemistry</i> , 55(8), 1578–1579. | | | |
| 566 | https://doi.org/10.1373/clinchem.2009.123752 | | | |
| 567 | Neuvonen, P. J. (1976). Interactions with the absorption of tetracyclines. <i>Drugs</i> , 11(1). | | | |
| 568 | 45–54. https://doi.org/10.2165/00003495-197611010-00004 | | | |
| 569 | O'Boyle, N. M., Banck, M., James, C. A., Morley, C., Vandermeersch, T., & | | | |
| 570 | Hutchison, G. R. (2011). Open Babel: An Open chemical toolbox. Journal of | | | |
| 571 | Cheminformatics, 3(10), 1–14. https://doi.org/10.1186/1758-2946-3-33/TABLES/2 | | | |
| 572 | Patel, K., Allen, S., Haque, M. N., Angelescu, I., Baumeister, D., & Tracy, D. K. | | | |
| 573 | (2016). Bupropion: a systematic review and meta-analysis of effectiveness as an | | | |
| 574 | antidepressant. Therapeutic Advances in Psychopharmacology, 6(2), 99. | | | |
| 575 | https://doi.org/10.1177/2045125316629071 | | | |
| 576 | Roy, R., Marakkar, S., Vayalil, M. P., Shahanaz, A., Anil, A. P., Kunnathpeedikayil, S., | | | |
| 577 | Rawal, I., Shetty, K., Shameer, Z., Sathees, S., Prasannakumar, A. P., Mathew, O. | | | |
| 578 | K., Subramanian, L. M., Shameer, K., & Yadav, K. K. (2022). Drug-food | | | |
| 579 | Interactions in the Era of Molecular Big Data, Machine Intelligence, and | | | |
| 580 | Personalized Health. Recent Advances in Food, Nutrition & Agriculture, 13(1), | | | |
| 581 | 27-50. https://doi.org/10.2174/2212798412666220620104809 | | | |
| 582 | Sanchez-Ruiz, A., & Colmenarejo, G. (2021). Updated Prediction of Aggregators and | | | |
| 583 | Assay-Interfering Substructures in Food Compounds. Journal of Agricultural and | | | |
| 584 | Food Chemistry, 69(50), 15184–15194. | | | |
| 585 | https://doi.org/10.1021/ACS.JAFC.1C05918 | | | |
| 586 | Seden, K., Dickinson, L., Khoo, S., & Back, D. (2012). Grapefruit-Drug Interactions. | | | |
| 587 | Drugs 2010 70:18, 70(18), 2373-2407. https://doi.org/10.2165/11585250- | | | |
| 588 | 00000000-00000 | | | |
| 589 | Sekine, M., Okamoto, K., Pai, E. F., Nagata, K., Ichida, K., Hille, R., & Nishino, T. | | | |
| 590 | (2023). Allopurinol and oxypurinol differ in their strength and mechanisms of | | | |
| 591 | inhibition of xanthine oxidoreductase. The Journal of Biological Chemistry, | | | |
| 592 | 299(9), 105189. https://doi.org/10.1016/J.JBC.2023.105189 | | | |
| 593 | Seth, R., Kydd, A. S. R., Buchbinder, R., Bombardier, C., & Edwards, C. J. (2014). | | | |
| 594 | Allopurinol for chronic gout. The Cochrane Database of Systematic Reviews, | | | |
| 595 | 2014(10), CD006077. https://doi.org/10.1002/14651858.CD006077.PUB3 | | | |
| 596 | Shoichet, B. K. (2004). Virtual screening of chemical libraries. <i>Nature 2004 432:7019</i> , | | | |
| 597 | 432(7019), 862-865. https://doi.org/10.1038/nature03197 | | | |
| 598 | Sica, D. A. (2006). Interaction of grapefruit juice and calcium channel blockers. <i>Am J</i> | | | |
| 599 | Hypertens, 19(7), 768–773. https://doi.org/10.1016/j.amjhyper.2005.11.003 | | | |
| 600 | Simon, J. A., Duncan, C., Carmody, T. P., & Hudes, E. S. (2004). Bupropion for | | | |
| 601 | Smoking Cessation: A Randomized Trial. Archives of Internal Medicine, 164(16), | | | |
| 602 | 1797–1803. https://doi.org/10.1001/ARCHINTE.164.16.1797 | | | |

| 603 | Sousa, S. F., Fernandes, P. A., & Ramos, M. J. (2006). Protein-ligand docking: Current | | |
|------------|---|--|--|
| 604 | status and future challenges. Proteins: Structure, Function and Genetics, 65(1), | | |
| 605 | 15–26. https://doi.org/10.1002/PROT.21082 | | |
| 606 | Stahl, S. M., Pradko, J., Haight, B. R., Modell, J. G., Rockett, C. B., & Learned- | | |
| 607 | Coughlin, S. (2004). A Review of the Neuropharmacology of Bupropion, a Dual | | |
| 608 | Norepinephrine and Dopamine Reuptake Inhibitor. Primary Care Companion to | | |
| 609 | The Journal of Clinical Psychiatry, 6(4), 159. | | |
| 610 | https://doi.org/10.4088/PCC.V06N0403 | | |
| 611 | Stielow, M., Witczyńska, A., Kubryń, N., Fijałkowski, Ł., Nowaczyk, J., & Nowaczyk, | | |
| 612 | A. (2023). The Bioavailability of Drugs—The Current State of Knowledge. | | |
| 613 | Molecules 2023, Vol. 28, Page 8038, 28(24), 8038. | | |
| 614 | https://doi.org/10.3390/MOLECULES28248038 | | |
| 615 | Takeda, T., Hao, M., Cheng, T., Bryant, S. H., & Wang, Y. (2017). Predicting drug- | | |
| 616 | drug interactions through drug structural similarities and interaction networks | | |
| 617 | incorporating pharmacokinetics and pharmacodynamics knowledge. Journal of | | |
| 618 | Cheminformatics, 9(1), 1-9. https://doi.org/10.1186/S13321-017-0200- | | |
| 619 | 8/FIGURES/4 | | |
| 620 | Tanimoto, T. T. (1958). An elementary mathematical theory of classification and | | |
| 621 | prediction. IBM Internal Report, 1–10. | | |
| 622 | Trott, O., & Olson, A. J. (2010). AutoDock Vina: Improving the speed and accuracy of | | |
| 623 | docking with a new scoring function, efficient optimization, and multithreading. | | |
| 624 | Journal of Computational Chemistry, 31(2), 455–461. | | |
| 625 | https://doi.org/10.1002/JCC.21334 | | |
| 626 | Vilar, S., Harpaz, R., Uriarte, E., Santana, L., Rabadan, R., & Friedman, C. (2012). | | |
| 627 | Drug-drug interaction through molecular structure similarity analysis. Journal of | | |
| 628 | the American Medical Informatics Association \Box : JAMIA, 19(6), 1066. | | |
| 629 | 1000000000000000000000000000000000000 | | |
| 630 | wei, J., Li, Z., Zhuo, L., Fu, X., wang, M., Li, K., & Chen, C. (2024). Enhancing drug- | | |
| 622 | supervised learning. Computers in Pielers and Medicine, 171, 108104 | | |
| 632 632 | https://doi.org/10.1016/I.COMPRIOMED.2024.108104 | | |
| 634 | Willott D Winterman V & Reauden D (1086) Implementation of Nearest Neighbor | | |
| 635 | Searching in an Online Chemical Structure Search System <i>Journal of Chemical</i> | | |
| 636 | Information and Computer Sciences 26(1) 36 41 | | |
| 637 | https://doi.org/10.1021/CI00049A008/ASSET/CI00049A008 FP PNG V03 | | |
| 638 | Wishart D S Guo A C Oler F Wang F Anium A Peters H Dizon R | | |
| 639 | Saveeda Z Tian S Lee B L Berjanskii M Mah R Yamamoto M Jovel | | |
| 640 | I Torres-Calzada C Hiebert-Giesbrecht M Lui V W Varshavi D Varshavi | | |
| 641 | D Gautam V (2022) HMDB 5.0. The Human Metabolome Database for | | |
| 642 | 2022. Nucleic Acids Research, 50(D1), D622–D631. | | |
| 643 | https://doi.org/10.1093/nar/gkab1062 | | |
| 644 | Won, C. S., Oberlies, N. H., & Paine, M. F. (2012). Mechanisms underlying food-drug | | |
| 645 | interactions: inhibition of intestinal metabolism and transport. <i>Pharmacology</i> & | | |
| 646 | Therapeutics, 136(2), 186–201. | | |
| 647 | https://doi.org/10.1016/J.PHARMTHERA.2012.08.001 | | |
| 648 | Yang, Y. L., Hua, K. F., Chuang, P. H., Wu, S. H., Wu, K. Y., Chang, F. R., & Wu, Y. | | |
| 649 | C. (2008). New cyclic peptides from the seeds of Annona squamosa L. and their | | |
| 650 | anti-inflammatory activities. Journal of Agricultural and Food Chemistry, 56(2), | | |
| 651 | 386–392. https://doi.org/10.1021/JF072594W | | |

- 652 Zaki, M. E. A., Al-Hussain, S. A., Masand, V. H., Akasapu, S., Bajaj, S. O., El-Sayed,
- N. N. E., Ghosh, A., & Lewaa, I. (2021). Identification of anti-sars-cov-2
- 654 compounds from food using qsar-based virtual screening, molecular docking, and
- molecular dynamics simulation analysis. *Pharmaceuticals*, *14*(4), 357.
- 656 https://doi.org/10.3390/PH14040357/S1
- 657 Zhang, Y., Neogi, T., Chen, C., Chaisson, C., Hunter, D. J., & Choi, H. K. (2012).
- 658 Cherry Consumption and the Risk of Recurrent Gout Attacks. Arthritis and
- 659 *Rheumatism*, 64(12), 4004. https://doi.org/10.1002/ART.34677
- 660

661

It is made available under a CC-BY-NC 4.0 International license .

663 **Figure 1**



664

Figure 1. (**A**) Scheme of the food-wide and drug-wide analysis to detect structural similarities between drugs and food compounds. (**B**) Snapshot of the FARFOOD application available at https://github.com/angelcroman. (**C**) Number of drugs with potential food interactions depending on the Tanimoto Index. (**D**) Histogram representing the different number of food compounds that present structural similarity to a specific drug.

671

It is made available under a CC-BY-NC 4.0 International license .





Figure 2. Pie charts categorizing the drugs that presented structural similarities with food compounds depending on (**A**) the molecular origin of the drug, (**B**) the structural properties of the drug, (**C**) the administration (oral or not) of the drug, (**D**) the fulfillment of the Rule-of-five or Rule of Lipinski, and (**E**) the novelty of the drug among its class.

680

681

It is made available under a CC-BY-NC 4.0 International license .

683 **Figure 3**



684

Figure 3. (**A**) Structures of lisinopril and cyclosquamosin A (top), as well as the docking results of both compounds against ACE (middle, bottom). (**B**) Results from patient surveys related to tropical (top) or other (bottom) fruit consumption and the presence of myocardial infarctions (M.I).

689

It is made available under a CC-BY-NC 4.0 International license .

Figure 4.





Figure 4. (A) Structures of bupropion and hydroxybupropion (top), as well as the docking results of both compounds against DAT (middle, bottom). (B) Results from patient surveys related to chestnut (top) or milk (bottom) consumption and the presence of episodes of mild or severe depression.

697

It is made available under a CC-BY-NC 4.0 International license .

699 **Figure 5**



700

Figure 5. (A) Results from patient (allopurinol) surveys related to beer consumption and the reference of number of affected joints (left), duration of gout crises (middle) and the number of gout crises (right). (B) Same as in A, but for meat consumption.

704

It is made available under a CC-BY-NC 4.0 International license .

Table 1. Demographic data of patients used in the study

| Drug | Sex (Female %) | Age (Mean/SD years) |
|-------------|----------------|---------------------|
| Lisinopril | 48% | 75.2/12.3 |
| Bupropion | 55% | 51.1/20.4 |
| Allopurinol | 22% | 73.1/18.8 |